Tags

Type your tag names separated by a space and hit enter

The safety of baricitinib in patients with rheumatoid arthritis.
Expert Opin Drug Saf. 2020 May; 19(5):545-551.EO

Abstract

Introduction: Despite improvement in disease outcomes and prognosis, a substantial number of patients with rheumatoid arthritis (RA) still require a novel agent for effective treatment. Baricitinib is a targeted synthetic disease-modifying antirheumatic drug (tsDMARDs) that selectively inhibits Janus kinase (JAK1/JAK2), an important enzyme in the pathogenesis of RA.Areas covered: This paper aimed to evaluate the pharmacodynamics and pharmacokinetics of baricitinib while reviewing its safety and efficacy in the treatment of RA.Expert opinion: Randomized controlled trials of baricitinib showed its efficacy and safety in patients with active RA who were methotrexate (MTX)-naïve or were not adequately responsive to MTX, conventional synthetic DMARDs, or tumor necrosis factor inhibitors. Baricitinib may be suitable in patients who prefer oral therapy and do not have a history of severe renal impairment, recent history of malignancy, or risk factors for adverse events (AEs) such as venous thromboembolism, opportunistic infection, and diverticulitis. Dose adjustment of baricitinib, based on the assessment of patient conditions including their renal function and disease activity, is an important strategy for successful and safe treatment. However, long-term post-marketing surveillance studies with a larger sample size are required to evaluate the overall safety and AEs with low incidence rates in clinical settings.

Authors+Show Affiliations

Department of Rheumatology, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.Department of Rheumatology, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32174196

Citation

Honda, Suguru, and Masayoshi Harigai. "The Safety of Baricitinib in Patients With Rheumatoid Arthritis." Expert Opinion On Drug Safety, vol. 19, no. 5, 2020, pp. 545-551.
Honda S, Harigai M. The safety of baricitinib in patients with rheumatoid arthritis. Expert Opin Drug Saf. 2020;19(5):545-551.
Honda, S., & Harigai, M. (2020). The safety of baricitinib in patients with rheumatoid arthritis. Expert Opinion On Drug Safety, 19(5), 545-551. https://doi.org/10.1080/14740338.2020.1743263
Honda S, Harigai M. The Safety of Baricitinib in Patients With Rheumatoid Arthritis. Expert Opin Drug Saf. 2020;19(5):545-551. PubMed PMID: 32174196.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The safety of baricitinib in patients with rheumatoid arthritis. AU - Honda,Suguru, AU - Harigai,Masayoshi, Y1 - 2020/03/21/ PY - 2020/3/17/pubmed PY - 2021/1/22/medline PY - 2020/3/17/entrez KW - Janus kinase inhibitor KW - Rheumatoid arthritis KW - baricitinib KW - efficacy KW - herpes zoster KW - safety SP - 545 EP - 551 JF - Expert opinion on drug safety JO - Expert Opin Drug Saf VL - 19 IS - 5 N2 - Introduction: Despite improvement in disease outcomes and prognosis, a substantial number of patients with rheumatoid arthritis (RA) still require a novel agent for effective treatment. Baricitinib is a targeted synthetic disease-modifying antirheumatic drug (tsDMARDs) that selectively inhibits Janus kinase (JAK1/JAK2), an important enzyme in the pathogenesis of RA.Areas covered: This paper aimed to evaluate the pharmacodynamics and pharmacokinetics of baricitinib while reviewing its safety and efficacy in the treatment of RA.Expert opinion: Randomized controlled trials of baricitinib showed its efficacy and safety in patients with active RA who were methotrexate (MTX)-naïve or were not adequately responsive to MTX, conventional synthetic DMARDs, or tumor necrosis factor inhibitors. Baricitinib may be suitable in patients who prefer oral therapy and do not have a history of severe renal impairment, recent history of malignancy, or risk factors for adverse events (AEs) such as venous thromboembolism, opportunistic infection, and diverticulitis. Dose adjustment of baricitinib, based on the assessment of patient conditions including their renal function and disease activity, is an important strategy for successful and safe treatment. However, long-term post-marketing surveillance studies with a larger sample size are required to evaluate the overall safety and AEs with low incidence rates in clinical settings. SN - 1744-764X UR - https://www.unboundmedicine.com/medline/citation/32174196/The_safety_of_baricitinib_in_patients_with_rheumatoid_arthritis_ L2 - https://www.tandfonline.com/doi/full/10.1080/14740338.2020.1743263 DB - PRIME DP - Unbound Medicine ER -